Increase in prevalence of autoimmune diseases, rise in technological advancements, and rise in awareness about early diagnosis are the major factors which drive the global market growth. Increasing ...

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a ...

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

The autoimmune testing landscape is shifting from single-analyte assays toward multiplex, high-sensitivity platforms capable of detecting multiple biomarkers from a single sample. Laboratories are ...

Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026.

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...

Add Yahoo as a preferred source to see more of our stories on Google. Autoimmune diseases are on the rise. It’s not just a hunch—autoimmune diseases are rising sharply, and the numbers are too ...

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief ...

CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering ...

Dublin, April 21, 2020 (GLOBE NEWSWIRE) -- The "Autoimmune Disease Diagnosis Market by Product (Consumables, Assay Kits, Instruments), Test Type (Inflammatory Markers, Routine Laboratory Tests), ...

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten ...